USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
https://doi.org/10.14412/2074-2711-2016-4-98-103
Abstract
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line oral teriflunomide in the treatment of MS in the Russian Federation (for 1 year) and second-line natalizumab and fingolimod. Among first-line oral drugs, dimethyl fumarate was shown to be superior to teriflunomide in a cost-effectiveness ratio and to be slightly ahead of the MS-modifying drugs (MSMDs) and the second-line drugs natalizumab and fingolimod. According to clinical and economic indicators, dimethyl fumarate is the drug of choise among other MSMDs in the treatment of MS.
About the Authors
V. R. Mkrtchyan
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
Russian Federation
Violetta Rafaelyevna Mkrtchyan.
43, Donskaya St., Moscow 115419, vrm1958@gmail.com
L. V. Brylev
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department; V.M. Buyanov City Clinical Hospital
Russian Federation
Russian Federation
43, Donskaya St., Moscow 115419; 26, Bakinskaya St., Moscow 115516
I. A. Shpak
Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
Russian Federation
43, Donskaya St., Moscow 115419
A. M. Sergeev
Institute of Applied Economic Researches, Russian Presidential Academy of National Economy and Public Administration
Russian Federation
Russian Federation
84, Vernadsky Prospect, Moscow 119606
References
1. Гусев ЕИ, Завалишина ИА, Бойко АН. Рассеянный склероз. Москва: Реал Тайм; 2011. 528 c. [Gusev EI, Zavalishina IA, Boiko AN. Rasseyannyi skleroz [Multiple sclerosis]. Moscow: Real Taim; 2011. 528 p.]
2. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag. 2016 Mar 2;12:339-50. doi: 10.2147/TCRM.S85099.eCollection2016.
3. Инструкция по применению лекарственного препарата для медицинского применения терифлуномид. [Instructions for use of teriflunomide.]
4. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
5. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97.
6. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098-107.
7. Dimethyl fumarate for treating relapsingremitting multiple sclerosis. Technology appraisal guidance. Published: 27 August 2014. https://www.nice.org.uk/guidance/ta320
8. TRANSPARENCY COMMITTEE Opinion 7 May 2014 TECFIDERA 120 mg, gastro-resistant hard capsule B/14 (CIP: 34009274 978 8 9) TECFIDERA 240 mg, gastroresistant hard capsule B/56 (CIP: 34009 274979 4 0) Applicant: BIOGEN IDEC FRANCEHAS – Medical, Economic and Public Health Assessment Division, 24 P.
9. Couto E, Hamidi V, Ringerike T, et al. Medicines used for Multiple Sclerosis –A Health Technology Assessment. Norwegian Institute of Public Health. http://www.kunnskapssenteret.no/en/publications/Medicines+used+for+Multiple+Sclerosis+A+Health+Technology+Assessment?vis=sammendrag.
10. Постановление Правительства РФ от 28.08.2014 № 871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи» [The decree of the RF Government dated 28.08.2014 No. 871 «On approval of Rules of forming of lists of medicinal preparations for medical application and the minimum assortment of medicinal preparations necessary for rendering of medical care»].
11. Приказ Министерства здравоохранения РФ от 24 декабря 2012 г. № 1542н «Стандарт первичной медико-санитарной помощи при рассеянном склерозе в стадии ремиссии» [Order of the Ministry of health of the Russian Federation of 24 December 2012 No. 1542n «Standard of primary health care in multiple sclerosis in remission»].
12. Приказ Министерства здравоохранения РФ от 20 декабря 2012 г. № 1085н «Об утверждении стандарта специализированной медицинской помощи при первом клиническом проявлении рассеянного склероза (клинически изолированном синдроме)» [Order of the Ministry of health of the Russian Federation of 20 December 2012 № 1085n [«On approval of the standard of specialized medical care at the first clinical manifestation of multiple sclerosis (clinically isolated syndrome)»].
Review
For citations:
Mkrtchyan V.R., Brylev L.V., Shpak I.A., Sergeev A.M. USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):98-103. (In Russ.) https://doi.org/10.14412/2074-2711-2016-4-98-103
Views: 587
Email this article 